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Abstract: Weight loss is key to controlling the increasing prevalence of metabolic syndrome (MS) and
its components, i.e., central obesity, hypertension, prediabetes and dyslipidaemia. The goals of our
study were two-fold. First, we characterised the relationships between eating duration, unprocessed
and processed food consumption and metabolic health. During 4 weeks of observation, 213 adults
used a smartphone application to record food and drink consumption, which was annotated for food
processing levels following the NOVA classification. Low consumption of unprocessed food and
low physical activity showed significant associations with multiple MS components. Second, in a
pragmatic randomised controlled trial, we compared the metabolic benefits of 12 h time-restricted
eating (TRE) to standard dietary advice (SDA) in 54 adults with an eating duration > 14 h and at least
one MS component. After 6 months, those randomised to TRE lost 1.6% of initial body weight (SD 2.9,
p = 0.01), compared to the absence of weight loss with SDA (−1.1%, SD 3.5, p = 0.19). There was
no significant difference in weight loss between TRE and SDA (between-group difference −0.88%,
95% confidence interval −3.1 to 1.3, p = 0.43). Our results show the potential of smartphone records
to predict metabolic health and highlight that further research is needed to improve individual
responses to TRE such as a shorter eating window or its actual clock time.
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1. Introduction
The prevalence of the metabolic syndrome (MS) is increasing worldwide, affecting
approximately 1 billion people [1]. Metabolic syndrome is a cluster of different clinical
conditions (referred to as MS components, i.e., central obesity, elevated blood pressure
(BP), impaired glucose tolerance, and dyslipidaemia) which share common mechanisms [2].
This puts a substantial proportion of the population at risk for cardio-metabolic diseases
such as myocardial infarction, stroke, diabetes, and their long-term complications [3].
Weight loss is a key factor for controlling MS components. Even a 5% weight loss is
associated with metabolic benefits [4], but most patients struggle to achieve and maintain
weight loss by lifestyle modifications (i.e., a healthier diet and increased physical activity).
Current pharmacological options are not always efficacious and tolerated [5], and bariatric
surgery is reserved for patients with severe obesity and requires close follow up [4]. This
explains the strong interest in new approaches to address isolated obesity (i.e., without
comorbidities) or multiple MS components.
Recent animal and human studies have highlighted the role of eating timing in ad-
dition to the amount of calorie intake. These approaches are often called intermittent or
periodic fasting and various dietary regimens on daily, weekly or monthly timescales are
proposed [6,7]. One form of intermittent fasting, called time-restricted eating (TRE), limits
energy intake to certain daily time intervals without restrictions on calories or macronutri-
ents [8,9]. In human studies, TRE can lead to weight loss even without deliberate calorie
restriction [10–14], which could result from a loss of both lean and fat mass [15]. Changes to
glucose metabolism have also been observed, with mixed effects on HbA1c [11,16], fasting
glucose [17], insulin sensitivity [18] or the area under the curve of continuous glucose
measurement [19]. An important and unaddressed question is whether TRE can lead to
health benefits beyond the standard dietary advice (SDA), which is part of the clinical
standard of care to address MS as a whole entity and its components such as isolated
obesity [4].
Mobile technologies hold great promise to track daily eating behaviour and improve
metabolic health as part of a daily routine. They offer potential advantages over more
traditional methods, such as food diaries or food questionnaires, by avoiding memory
recall bias and minimising negative feedback and the Hawthorne observer effect [20]. In a
landmark study using the smartphone application MyCircadianClock, Gill and Panda [10]
remotely collected data on eating behaviour to identify adults that may benefit from TRE.
Once data are remotely collected, a key question is how to optimally characterise the
relationship between the ingestion events and metabolic health. One possibility is to use
photographs and annotations to estimate the number of calories in each consumed meal
and drink. This requires either asking participants to record exact weights and ingredients
of meals [21] or a semi-quantitative estimation of all pictures by trained dietitians based on
reference tables and standard recipes. Beyond calories and macronutrient content, food
quality can be assessed using systems such as the NOVA classification, which uses four
categories to rank food from unprocessed to ultra-processed [22–24]. To date, it is not
established whether NOVA classification of food and drink events recorded by smartphone
carries predictive information across multiple metabolic health indicators.
The goals of our study were two-fold. First, we characterised the relationships be-
tween eating duration, unprocessed and processed food consumption, lifestyle factors
and metabolic health using a smartphone application in the Swiss adult population over
4 weeks. Second, we investigated whether a 12 h TRE leads to an improvement in MS
components compared to SDA in a pragmatic randomised controlled trial lasting 6 months.
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2. Materials and Methods
The SwissChronoFood trial was an open-label pragmatic randomised controlled trial
evaluating the metabolic effects of TRE versus SDA (clinicaltrials.gov no. NCT03241121,
Kofam.ch no. SNCTP000002259). People aged ≥ 12 years were eligible, although only
adults (≥18 years old) are reported in this article. Each participant signed a written consent
form (see Institutional Review Board Statement below).
2.1. Study Design and Intervention
The study comprised an observation phase to assess the baseline metabolic parameters
and the daily eating behaviour of community-based adults using a research-dedicated
smartphone application over 4 weeks. We recruited via posters, online adverts and social
media in two different languages and cultural regions of Switzerland, i.e., at Lausanne
University Hospital, Lausanne and at Inselspital, Bern. Inclusion criteria were adults with
a body mass index (BMI) ≥ 20 kg/m2, stable weight (±2 kg) over the previous 3 months,
and the regular and confident use of a smartphone compatible with the MyCircadianClock
application (iOS or Android systems) [10].
After 4 weeks of observation, individuals with an eating duration (defined below)
of >14 h and had at least one component of MS were eligible for the intervention phase
(Supplementary Materials Figure S1). The criteria of each MS component followed the
International Diabetes Foundation (IDF) consensus definition [2]: central obesity was
defined as BMI ≥ 30 kg/m2 or waist circumference (WC) ≥ 80 cm (women) or WC ≥ 94 cm
(men); hypertension as systolic BP ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg; impaired
fasting glucose for plasma levels ≥ 5.6 mmol/L (100 mg/dL); high triglycerides for fasting
plasma levels ≥ 1.7 mmol/L (150 mg/dL); and low HDL cholesterol for fasting plasma
levels < 1.29 mmol/L (50 mg/dL, women) or <1.03 mmol/L (40 mg/dL, men).
In the intervention phase, participants were randomised to the TRE or SDA interven-
tion, with a 1:1 allocation ratio and block randomisation of 8 units stratified by sex and
recruitment site. The intervention could not be blinded, but the allocation table was
computer-generated and concealed. Those in the TRE arm were asked to limit their con-
sumption of food and calorie-containing drinks to a 12 h window of their choice, with no
advice on nutrition quality, quantity of macronutrients or calorie intake. Those in the SDA
arm received a 10 min nutritional counselling at randomisation. They were given a leaflet
summarising the food pyramid and Swiss recommendations for a balanced and healthy
diet [25,26] that is considered the standard of care and does not provide advice on calorie
intake. After 6 months, the metabolic measurements were repeated at the closeout visit. In
addition, participants were contacted at 2 and 4 months post-randomisation to self-report
their body weight and address compliance with the intervention.
In addition to the eligibility criteria listed above, we excluded from the observation
phase pregnant and breastfeeding women, individuals with a major illness/surgery over
the previous month, active cancer or under treatment over the previous 12 months, eating
disorder, prior bariatric surgery, those who had been following a weight management
programme over the previous 3 months, shift workers and those travelling to a differ-
ent time zone during the observation phase. Additionally for the intervention phase, we
excluded before randomisation adults with cardiovascular disease (e.g., coronary heart
disease, cerebrovascular disease, peripheral artery disease), major liver, gastrointestinal,
renal, endocrine or sleep disorders, diabetes mellitus with hypoglycaemic drug(s), those
on centrally acting medications (benzodiazepines, zolpidem, zopiclone, antidepressants,
neuroleptics and psychotropic drugs), lipid-lowering drugs and medications affecting gut
absorption, transit or weight.
Modifications to the study protocol. In the original protocol, we planned to ran-
domise only participants with MS following the IDF consensus definition, i.e., those
with central obesity and at least two other MS components [2]. This population proved
difficult to recruit because the Swiss adult population has a lower prevalence of obesity
than in most Western countries [27] thus leading to an even lower prevalence of MS. The
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inclusion criteria for the intervention phase were relaxed after 5 months of recruitment:
those with an eating duration >14 h and had at least one component of MS were eligible
for the intervention phase (Figure S1).
2.2. Recording Food and Drink Events with a Smartphone Application
Participants were instructed to take pictures of all consumed food, drinks and medica-
tions with the research-dedicated myCircadianClock smartphone application [10]. Recorded
entries included a timestamped picture and a free-text annotation. Participants could anno-
tate photographs either immediately or in the following hours. Optionally, participants
could type text-only entries without any picture, e.g., if the smartphone ran out of battery,
or if it was not socially acceptable to take pictures in the current context.
The eating duration was determined as the time interval during which participants
consumed food items and drinks daily and was calculated from the timestamps of all
recorded ingestion events (food items, drinks, except for water and medications) [10,15].
In order to be less sensitive to outliers (special days with time shifts in ingestion events)
or entry errors, the eating duration was defined as the time interval between the 2.5th
and the 97.5th percentiles of all timestamped ingestion events during the observation
phase. To account for the social consumption habits and the nadir of food entries, we
calculated the percentiles using a start time of 04:00 as defined previously [10], which
also corresponded to a low point of ingestion events in this study (Figure S2). The eating
duration of the intervention phase was estimated in a similar fashion. Participants did
not receive feedback on their eating duration until the end of the observation phase. They
were regularly reminded to record ingestion events at planned regular phone calls or via
email after 2 weeks of observation, and after 2 and 4 months of intervention (Figure S1).
No imputation for missing data was carried out, but we analysed the number of ingestion
events in a post-hoc analysis (see Section 3.6).
2.3. Categorising Ingestion Events Based on Free-Text Annotations
We developed an analysis pipeline using Python scripts to categorise the free-text
annotations of recorded ingestion events in the observation and intervention phases. To
ensure good coverage and improve the number of text entries with an assigned NOVA
category, we performed the following pre-processing steps: (1) Each text entry containing
multiple food items separated by commas was split into multiple text entries; (2) num-
bers, semi-quantitative terms (e.g., “slice”, “glass”, “piece”, “half”), units (e.g., “grams,”
“decilitres”) and multiple blank spaces were removed. (3) We then counted the number of
unique text entries using the Tokenizer function in Keras (Python module, version 2.2.4).
Free-text annotations sometimes comprised typos and spelling variations, and to correct
for this we further processed words based on the Levenshtein distance (Python module
python–Levenshtein, version 0.12.0). The Levenshtein distance between two words is the
minimum number of single-character changes (substitutions, insertions or deletions) that
is required to transform one word into the other. For any two entries with a Levenshtein
distance of one, the entry with the largest number of counts was preferred, e.g., “ham piza”
would be transformed into “ham pizza” if the second entry had more counts across all
recordings. (4) Finally, text entries that were recorded only once were not included in this
analysis. From a total of 17,438 unique entries, 11,030 were recorded once and 6408 were
recorded more than once, but this filtering still gave high coverage due to the fact that
some items are frequently used. For example, the top entry “cafe” (“coffee” in English,
“Kaffee” in German, and many other spelling variants) was used 3031 times. The full list of
recorded entries (including the single entries), their frequencies and processing steps are
included as Supplementary Materials File S1.
We assessed food processing according to the qualitative NOVA classification, which
uses four categories to rank food from unprocessed to ultra-processed [22–24]. No quanti-
tative assessment of the macronutrient intake, number of calories or types of food items
was attempted. In addition to the 4 NOVA categories (NOVA1: “Unprocessed or mini-
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mally processed foods”, NOVA2: “Processed culinary ingredients”, NOVA3: “Processed
foods”, NOVA4: “Ultra-processed foods”), we added categories for beverages grouped
into “Alcohol-containing drinks” (A), “Caffeinated drinks” (C), “Sweet drinks” (S), and
“Other drinks” (D). With this extended classification, each drink entry could therefore be
assigned multiple categories. For example, the soda Coca-Cola was an ultra-processed,
caffeinated and sweet drink (abbreviated NOVA4-CS), coffee with sugar and milk was
a NOVA2, caffeinated and sweet drink (abbreviated NOVA2-CS) and a black tea was a
NOVA1, caffeinated drink (abbreviated NOVA1-C).
The pre-processed text entries were annotated using the extended NOVA classification
by 4 independent reviewers (J.M., N.E.P., S.U., T.-H.C.). A category was assigned to a
given entry if a minimum of 3 reviewers selected the category. A consensus was reached
for the remaining entries by at least 3 reviewers. For entries collected in German (at
the Bern research site), representing 16.4% of all entries, the entries were annotated by a
single reviewer (T.-H.C.) due to the language considerations. Some food entries required
assumptions on their base recipes and ingredients. Items were assumed to be homemade
unless stated otherwise [28,29], with limited exceptions (e.g., chocolate-containing food
and drinks, biscuits, toast and soft bread, croissants, pizza, burgers, plant-based drinks)
because they most often involve food processing. A single dish composed of multiple items
and ingredients was assigned the highest single NOVA category based on their base recipe.
A full list of annotated entries is provided in the Supplementary Materials File S2.
2.4. Quantifying Compliance to the Study Intervention
For participants randomised to TRE or SDA, we quantified their compliance to the
allocated intervention by comparing their ingestion events during the intervention phase
to those recorded during the observation phase. We quantified the eating duration (de-
fined in Section 2.2) and the percentage of ingestion events belonging to each NOVA and
drink category (defined in Section 2.3). This was done separately for the observation
and intervention phases to calculate the changes (∆) pre- and post-randomisation. The
compliance of participants in the TRE arm was assessed according to their eating duration
in the intervention phase. Participants in the SDA arm were considered compliant if the
proportion of ingestion events with a NOVA4 category decreased and the proportion of
ingestion events with NOVA1 categories increased.
2.5. Primary and Secondary Outcomes, Other Measurements
The primary outcome of the study was the change in weight after 6 months following
the 12 h TRE versus SDA intervention. Weight was measured in light clothing with
calibrated medical-grade scales at baseline (visit 1), at randomisation (visit 3) and after
6 months of follow up (visit 6, Figure S1). In addition, weight was measured at home and
recorded at interim phone calls (visits 4 and 5). Because these weights were self-reported,
they were analysed in a secondary analysis.
The secondary outcomes were the changes in BMI, WC, BP, and fasting plasma
concentrations of glucose, HDL cholesterol and triglycerides. The BMI was calculated
as the weight in kilograms divided by the height in metres squared. The height was
measured barefoot using a calibrated stadiometer. Blood pressure was measured three
times with a calibrated monitor (Omron Intellisense® BP monitor, Omron Healthcare) and
an appropriately sized arm cuff, after 5 min of rest in the sitting position, and the last two
values were averaged.
We measured other metabolic parameters, such as glycated haemoglobin (HbA1c),
using standard biochemistry assays at the same time points. Body composition was
measured by whole-body dual-energy X-ray absorptiometry (DXA, GE Healthcare Lunar
iDXA at Lausanne site, GE Healthcare Lunar Prodigy Advance at Bern site) following
international guidelines [30]. With minimal ionising radiation, DXA can assess total
lean mass, fat mass and body fat percentage [31]. The visceral adipose tissue (VAT)
was computed by subtracting subcutaneous adipose tissue from the total android fat
Nutrients 2021, 13, 1042 6 of 19
mass [32]. At baseline, sleep quality was assessed with the Pittsburgh Sleep Quality Index
(PSQI) [33] and physical activity with the short form of the International Physical Activity
Questionnaire (IPAQ) [34]. Sleep duration and the midpoint of sleep were assessed on
workdays and free days using the Munich Chronotype Questionnaire [35].
2.6. Statistical Analyses
Data are reported as the mean ± standard deviation (SD) or median (interquartile
range, IQR) if not normally distributed. Comparisons between groups or sex were calcu-
lated with the Chi2 statistic (or exact Fisher test where appropriate) for categorical variables
or the Student’s t-test for continuous variables. Paired sample t-tests were performed
(Scipy module in Python, version 1.2.1; Stata software package, version 16.1) to test for the
null hypothesis that pre- and post-intervention measurements had identical mean values.
Non-paired t-tests were used to compare the differences between the TRE and control
group (which have different numbers of participants). A two-tailed p-value < 0.05 was con-
sidered statistically significant, without correction for multiple comparisons. All analyses
were performed with the intention-to-treat approach, although we also assessed weight
changes in a secondary per-protocol analysis.
Sample size calculations were based on general assumptions as no randomised con-
trolled trial of TRE was published at the time of study design. Gill and Panda [10] reported
a weight loss of 3.27 kg (approximately SD 1.18) after TRE and we expected the standard-
of-care SDA to result in a weight loss of 1.0 kg (approximately SD 1.0), although this varies
depending on the participant’s motivation and the intervention intensity. Using an alpha
level of 0.05, a power of 90% and an estimated attrition rate of 25%, this difference was
expected to be observed with 20 participants (10 in the TRE arm, 10 in the SDA arm).
Bayesian linear regression [36] was performed using data from the observation phase
to quantify the relationship between the explanatory variables and the outcome variables
(clinical measurements related to metabolic health). The explanatory variables included
age, sex, the number of ingestion events for each of the NOVA and drink categories, eating
duration, the midpoint of sleep on work/free days, sleep duration on work/free days,
sleep quality (PSQI) and physical activity (IPAQ). For each of the participants i = 1, . . . , N,
there was a set of K explanatory variables xi = (xi1, . . . , xiK) and a set of D clinical mea-
surements yi = (yi1, . . . , yiD). The linear regression model for each clinical measurement d








where for each clinical measurement d, there is a vector of regression coefficients βd =
(βd1, . . . , βdK) and a parameter σd to quantify the SD of the observation error. The clinical
measurements were log-transformed before further analyses to make the distributions
closer to a normal distribution, and the IPAQ questionnaire result was transformed using a
square root operation. We normalised both the clinical measurements and the explanatory
variables by subtracting the mean and dividing by the standard deviation. In the Bayesian
regression, we used priors of σd ∼ N(0, 1) and βdk ∼ N(0, 0.1) to regularise the inference
problem. Posteriors for the regression coefficients and parameters were inferred by the
Hamiltonian Monte Carlo sampler in the STAN probabilistic programming language [37]
with 4 different chains of 1000 samples each. To perform variable selection, we fitted the
model with all variables and then only selected variables if 95% of the parameter estimates
were greater or less than one. To validate predictive performance of the regression models
we performed leave-one-out cross-validation (LOO-CV) whereby a test participant was
removed from the data and the model was optimised using the remaining participants.
The R2 value was then calculated using the predictions on the test participants.
For participants randomised to TRE or SDA, we performed a secondary analysis using
the weight measurements at visits 1 and 3 (the observation phase) and visit 6 (6 months
after the start of intervention), as well as the self-reported weights at visits 4 and 5 (2 and
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4 months after start of intervention, respectively). For each participant, we could then
estimate the change in weight using the following quadratic model
y(t) = a + bt + ct2 + ε
where y(t) is the weight measurement (kg) at time t, t is time in months after the start of
intervention, a is the starting weight (kg), b is the regression coefficient for the linear rate of
weight loss (in kg/per month) while c is the regression coefficient for the quadratic term
(in kg/per month2) and ε is a normally distributed noise term with mean 0 and standard
deviation σε to account for measurement noise and natural fluctuations in weight. The
quadratic term was included to account for a weight time series that showed a nonlinear,
curved profile. The two weight measurements in the observation phase (visits 1 and
3) were considered as t = 0. We used weakly informative priors on the parameters
b, c, σε ∼ N(0, 10) and again used sampling within STAN to estimate the parameters.
After performing parameter inference, this approach provided confidence bounds on the
weight change for each participant.
3. Results
3.1. Recruitment of Participants
Out of the 729 adults screened for eligibility, 511 did not meet the criteria (detailed
in Figure 1). We included 218 adults in the observation phase but had to exclude five
individuals just after inclusion for undisclosed psychiatric disorders or a BMI lower than
self-reported. Accounting for these exclusions, the observational data of 213 adults could
be analysed. Next, we randomised 28 participants to TRE and 26 to SDA intervention. Two
individuals allocated to the SDA arm had to be excluded the day after randomisation [38],
when it was learnt that they met exclusion criteria for the intervention phase (regular use
of statin or antidepressant).
3.2. Baseline Characteristics of the Participants
The 213 adults in the observation phase had a mean age of 40.1 years (SD 13.3,
range from 18 to 77) and 71% were women (Table 1). The median BMI was 24.9 kg/m2
(IQR 22.6–29.1). Central obesity was found more often in women (55%) than in men (39%,
p = 0.04). On the other hand, hypertension, impaired fasting glucose and elevated triglyc-
erides were more prevalent among men than women (all p ≤ 0.002). While the mean
fasting plasma glucose was 5.2 mmol/L (SD 0.6) in men and 4.9 mmol/L (SD 0.5) in
women (p = 0.0001), the HbA1c levels were comparable between sex (p = 0.19).
Following the IDF definition [2], the prevalence of MS was not statistically different
between men (21%) and women (11%, p = 0.055). When looking at MS components sepa-
rately, 38% had no MS component, 27% a single MS component, 21% two MS components,
and 14% three or more MS components. We therefore decided to include participants with
at least one MS component at baseline (Section 2.1).
3.3. Relationship between Metabolic Health, Unprocessed and Processed Food Consumption
at Baseline
A total of 88.7% of ingestion events (out of 102,072 events) were annotated according
to the expanded NOVA classification, of which 2.4% were removed as they were water or
non-sweetened flavoured water, 1.2% were medications and 1.5% had text that was not
sufficiently informative to be fully annotated. The remaining 11.3% of ingestion events
were not annotated because they represented single entries. Of the annotated ingestion
events, unprocessed or minimally processed foods (NOVA1) represented 45.9%, processed
culinary ingredients (NOVA2) 13.1%, processed foods (NOVA3) 18.2%, and ultra-processed
foods (NOVA4) 22.9%. Drink entries were also classified according to the newly devised
categories: Alcohol-containing drinks (NOVA-A) represented 2.9% of the annotated entries,
caffeinated drinks (NOVA-C) 11.1%, sweet drinks (NOVA-S) 2.5% and other drinks (NOVA-
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D) 5.0%. Some entries were designated multiple categories, and the overlap between
different categories is shown in Table S1.










Age, mean (SD) 40.2 (13.3) 40.1 (13.4) 40.1 (13.3) 0.96
Marital status b, n (%) 0.92
Married, partnership 96 (72%) 39 (71%) 135 (71%)
Single, separated, widow(er) 38 (28%) 16 (29%) 54 (29%)
Education b, n (%) 0.23
Primary, secondary 16 (10%) 6 (10%) 22 (10%)
Apprenticeship, vocational 27 (18%) 7 (12%) 34 (16%)
Professional school 27 (18%) 6 (10%) 33 (16%)
University, or higher degree 81 (54%) 41 (68%) 122 (58%)
Born in Switzerland, n (%) 94 (62%) 37 (61%) 131 (62%) 0.87
Clinical characteristics
Weight, kg, median (IQR) 69.0 (62.7–80.1) 83.6 (74.2–95.5) 73.3 (65.0–84.2) <0.0001
BMI, kg/m2, median (IQR) 24.6 (22.2–29.0) 25.3 (23.4–29.5) 24.9 (22.6–29.1) 0.16
BMI < 25.0 kg/m2, n (%) 81 (53%) 29 (48%) 110 (52%)
BMI 25.0–29.9 kg/m2, n (%) 40 (26%) 18 (30%) 58 (27%)
BMI ≥ 30.0 kg/m2, n (%) 31 (20%) 14 (23%) 45 (21%)
WC, cm, median (IQR) 81.8 (73.5–92.3) 90.0 (81.0–101.5) 84.5 (75.5–97.0) 0.0001
Current smokers, n (%) 21 (14%) 13 (21%) 34 (16%) 0.18
Cardiovascular disease c, n (%) 3 (2%) 5 (8%) 8 (4%) 0.045
Endocrine disorder d, n (%) 14 (9%) 0 14 (7%) 0.01
Respiratory disorder, n (%) 20 (13%) 10 (16%) 30 (14%) 0.54
Metabolic syndrome (MS) e
MS components, n (%)
1. Central obesity 84 (55%) 24 (39%) 108 (51%) 0.04
2. Hypertension 30 (20%) 26 (43%) 56 (26%) <0.001
3. Impaired fasting glucose 13 (9%) 17 (29%) 30 (14%) <0.001
4. High triglycerides 12 (8%) 14 (24%) 26 (12%) 0.002
5. Low HDL-cholesterol 21 (14%) 6 (10%) 27 (13%) 0.46
MS by the IDF definition, n (%) 17 (11%) 13 (21%) 30 (14%) 0.055
Lifestyle
Sleep duration f, hours, mean (SD) 7.47 (0.94) 6.99 (0.80) 7.33 (0.93) <0.001
Sleep quality g, mean (SD) 5.3 (2.8) 5.0 (2.8) 5.2 (2.8) 0.31
Physical activity h, median (IQR) 1289 (687–2232) 1884 (930–2849) 1386 (693–2598) 0.06
a p-Value for comparison between both sexes calculated with Chi2 statistics (or exact Fisher test where appropriate) for categorical variables,
Student’s t-test for continuous variables with normal distribution, and Wilcoxon–Mann–Whitney rank-sum test for continuous variables
with non-normal distribution. b The data on marital status were available for 189 individuals, and the highest level of education for 211
individuals. c Cardiovascular disease prior to the inclusion in the study, e.g., coronary heart disease, cerebrovascular disease, peripheral
artery disease. d Mostly hypothyroidism with thyroxine replacement at a stable dosage. e The metabolic syndrome (MS) and its components
were defined as follows [2]: central obesity was defined as a body mass index (BMI) ≥ 30 kg/m2 or waist circumference (WC) ≥ 80 cm
(women) or WC ≥ 94 cm (men); hypertension as systolic blood pressure (BP) ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg; impaired
fasting glucose for plasma levels ≥ 5.6 mmol/L (100 mg/dL); high triglycerides if ≥1.7 mmol/L (150 mg/dL); and low HDL cholesterol if
<1.29 mmol/L (50 mg/dL, women) or <1.03 mmol/L (40 mg/dL, men). f Weighted average of sleep duration between workdays and off
days. g Sleep quality was assessed among 212 individuals with the Pittsburgh Sleep Quality Index (PSQI), ranging from 0 (no issues) to 21
points (extreme disturbance of sleep quality) [33]. h Physical activity was assessed among 207 individuals with the International Physical
Activity Questionnaire (IPAQ), expressed in MET-minutes per week [34].
We next examined whether age, sex, eating duration, NOVA classification of ingestion
events and questionnaires on sleep and physical activity contained predictive information
for each metabolic health parameter at baseline in a Bayesian linear regression. We only
report here the significant coefficients (Figure 2A). The regression coefficient for age was
significant for all metabolic health parameters except HDL cholesterol. The regression
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coefficient for sex was significant for five out of eight of the metabolic health parameters,
and the estimated coefficients for women were negative for WC, systolic BP, triglycerides
and glucose, which is in line with their lower values typically seen among women. Out of
the ingestion events, the number of unprocessed food items (NOVA1) had the highest pre-
dictive performance. It was negatively associated with BMI and diastolic BP, and positively
associated with HDL cholesterol. The ingestion of ultra-processed food items (NOVA4)
was positively associated with WC. The consumption of alcohol-containing drinks (NOVA-
A) was positively associated with HDL cholesterol and both caffeinated (NOVA-C) and
sweet drinks (NOVA-S) with triglyceride levels. From the sleep questionnaires, a negative
relationship was found between sleep duration on workdays and BMI and WC. Finally, the
level of physical activity (IPAQ) was negatively associated with BMI, WC and triglycerides,
and positively associated with HDL cholesterol.




Figure 1. Flow of participants. Adapted from Reference [39]. Out of the 729 adults screened for eligibility, 213 were analysed in 
the observation phase and 54 were randomised to 12 h time-restricted eating (TRE) versus standard dietary advice (SDA). Dur-
ing the intervention phase, two participants had to be excluded the day after randomisation (see text), five were lost to follow 
up and two withdrew from the study (due to the Covid-19 pandemic or other reasons). The main analyses therefore comprised 
25 participants in the TRE arm and 20 participants in the SDA arm. 
3.2. Baseline Characteristics of the Participants 
The 213 adults in the observation phase had a mean age of 40.1 years (SD 13.3, range 
from 18 to 77) and 71% were women (Table 1). The median BMI was 24.9 kg/m2 (IQR 22.6–
29.1). Central obesity was found more often in women (55%) than in men (39%, p = 0.04). 
On the other hand, hypertension, impaired fasting glucose and elevated triglycerides 
were more prevalent among men than women (all p ≤ 0.002). While the mean fasting 
plasma glucose was 5.2 mmol/L (SD 0.6) in men and 4.9 mmol/L (SD 0.5) in women (p = 
0.0001), the HbA1c levels were comparable between sex (p = 0.19). 
Following the IDF definition [2], the prevalence of MS was not statistically different 
between men (21%) and women (11%, p = 0.055). When looking at MS components sepa-
rately, 38% had no MS component, 27% a single MS component, 21% two MS components, 
and 14% three or more MS components. We therefore decided to include participants with 








































Assessed for eligibility 
(n = 729)
Randomised (n = 54)
Allocated to TRE intervention (n = 28)
• Lausanne site (n = 24)
• Bern site (n = 4)
Received allocated TRE intervention (n = 28)
Excluded (n = 511)
• Diet, intermittent fasting or recent weight loss (n = 30)
• Shift worker, travelling or living abroad (n = 35)
• Recent illness, surgery, pregnancy, diabetes (n = 22)
• Lack of interest, of time, or no reason provided (n = 424)
Lost to follow-up (n = 2)
Withdrawn (n = 1): Covid-19 pandemic + surgery
Analysed in the TRE arm (n = 25) 
Excluded from analysis (n = 3): Incomplete 
clinical data at close-out (visit 6)
Lost to follow-up (n = 3)
Withdrawn (n = 1): Covid-19 pandemic
Analysed in the SDA arm (n = 20) 
Excluded from analysis (n = 4): Incomplete 
clinical data at close-out (visit 6)
Allocated to SDA intervention (n = 26)
• Lausanne site (n = 20)
• Bern site (n = 6)
Received allocated SDA intervention (n = 24)
Included in the observation 
phase (n = 218)
Lost to follow-up (n = 3)
Withdrawn (n = 7): lack of time, study too restrictive,
or no reason provided
Not eligible for the RCT (n = 149, ≥ 1 reason possible):
• No metabolic syndrome component (n = 93)
• Eating duration < 14 h (n = 94)
• Refused the intervention and follow-up (n = 93)
Exclusion criteria revealed after 
randomisation (n = 2): 
anti-depressant, statin 
recently started
Analysed in the 
observation phase (n = 213)
Exclusion criteria revealed after inclusion (n = 5):
psychiatric disorders, BMI lower than self-reported
. f rticipants. dapted from Reference [39]. Out of the 729 adults creened for eligibility, 213 were analysed
in the observation phase and 54 w re randomised to 12 h time-restricted eating (TRE) versus standar i t i ( ).
During the intervention phase, two participants had to be excluded the day after randomisation (see text), five were lost to
follow up and two withdrew from the study (due to the Covid-19 pandemic or other reasons). The main analyses therefore
comprised 25 participants in the TRE arm and 20 participants in the SDA arm.
Nutrients 2021, 13, 1042 10 of 19




Figure 2. The addition of NOVA categories and physical activity to age and sex increases the predictive power for MS components. 
(A) Each row shows the regression coefficients for predicting the clinical variable (labelled on the y-axis) using the explanatory vari-
ables (labelled on the x-axis), all measured in the observation phase. BMI, body mass index; BP, blood pressure; HbA1c, glycated 
haemoglobin; HDL chol., high-density lipoprotein cholesterol; NOVA count, the number of ingestion events of each NOVA category; 
NOVA-A, alcohol-containing drinks; NOVA-C, caffeinated drinks; NOVA-S, sweet drinks; NOVA-D, other drinks; Midsleep W and 
Midsleep F, the midpoint of sleep on workdays and free days, respectively; Sleep duration W and Sleep duration F, the sleep duration 
on workdays and free days, respectively; Waist circ., waist circumference. The regression coefficients show the mean posterior pa-
rameter estimate, and variables that are not significant are shown as white space. The red colour corresponds to a positive coefficient, 
and the blue colour a negative coefficient. (B) Bar heights represent the R2 values calculated on test participants using leave-one-out 
cross-validation (LOO-CV) to compare the predictive performance of a model that uses only age and sex (green bars) versus a model 
that uses all variables that were significant (orange bars, selected variables in panel (A)). 
3.4. Compliance with the Randomly Assigned Interventions 
We evaluated the changes in the fraction of NOVA categories and in eating duration 
between study phases to quantify compliance to each intervention (i.e., TRE and SDA) 
after randomisation. 
Relative to baseline, those in the SDA arm significantly increased the proportion of 
unprocessed or minimally processed food (NOVA1, +7.0%, SD 9.7, p < 0.01) and signifi-
cantly decreased the proportion of ultra-processed food (NOVA4, −7.6%, SD 11.0, p < 0.01, 
Figure 3A). The increased consumption of NOVA1 items and decreased consumption of 
NOVA4 items in the SDA group were significant compared to TRE (p < 0.01 and p = 0.04, 
respectively, Table S2). No significant changes were observed for the consumed drink cat-
egories. 
The timestamp of each ingestion event allowed the assessment of changes in eating 
duration during the intervention phase (Figure 3B,C). The TRE intervention shortened the 
eating duration compared to baseline (−3.0 h, SD 1.6), which was due to the later start of 
the eating interval (+1.5 h, SD 1.1) and an earlier end of the eating interval (−1.4 h, SD 1.1, 
all p < 0.01). Changes in the eating interval after TRE were all statistically significant com-
pared to SDA (all p < 0.01 for pairwise comparisons, Table S2). 
The changes in NOVA categories in the SDA arm on the one hand, and changes in 
eating duration in the TRE arm on the other hand, confirm that participants followed the 































































































































































Figure 2. The addition of NOVA categories and physical activity to age and sex increases the predictive power for MS
components. (A) Each row shows the regression coefficients for predicting the clinical variable (labelled on the y-axis)
using the explanatory variables (lab lled on the x-axis), all measured in the observation phase. BMI, body mass index; BP,
blo d pressure; HbA1c, glycated haemoglobin; HDL chol., high-densi y lipoprotein cholester l; NOVA count, the number
of ingestion events of each NOVA category; NOVA-A, alcohol-containing drinks; NOVA-C, caffeinated drinks; NOVA-S,
sweet drinks; NOVA-D, other drinks; Midsleep W and Midsleep F, the midpoint of sleep on workdays and free days,
respectively; Sleep duration W and Sleep duration F, the sleep duration on workdays and free days, respectively; Waist circ.,
waist circumference. The regression coefficients show the mean posterior parameter estimate, and variables that are not
significant are shown as white space. The red colour corresponds to a positive coefficient, and the blue colour a negative
coefficient. (B) Bar heights represent the R2 values calculated on test participants using leave-one-out cross-validation
(LOO-CV) to compare the predictive performance of a model that uses only age and sex (green bars) versus a model that
uses all variables that were significant (orange bars, selected variables in panel (A)).
Given that age and sex were frequently found to have significant regression coefficients
(Figure 2A), we wanted to confirm that the inclusion of the additional explanatory variables
from ingestion events and questionnaires increased predictive performance. Indeed, the
R2 values calculated on test participants using leave-one-out cross-validation (LOO-CV)
showed that inclusion of those variables increased predictive performance for BMI, WC,
HDL cholesterol and triglycerides, while there was no improvement in performance over
age and sex alone for systolic and diastolic BP, glucose and HbA1c (Figure 2B). Of note,
there was a negative relationship between eating duration and sleep on workdays and
glucose levels, but this did not lead to substantially increased predictive performance when
these variables were included.
3.4. C mpliance with the Randomly Assigned Int rventions
We evaluated the changes in the fraction of NOVA categories and in eating durati n
betwee study phases to quantify compli nc to each interve tion (i.e., TRE and SDA)
after randomis tion.
Relative to baseline, those n th SDA arm significantly increased the proportion of
unproc ssed or minimally processed food (NOVA1, +7.0%, SD 9.7, p < 0.01) and signifi-
c ntly ecreased the proportion f ultra-processe fo d (NOVA4, −7.6%, SD 11.0, p < 0.01,
Figure 3A). The increased cons mption of NOVA1 ems and decreased consumption
of NOVA4 items in the SDA group were significant compared to TRE (p < 0.01 and
p = 0.04, respectively, Table S2). No significant changes were observed for the consumed
drink categories.




Figure 3. Changes in the consumption of NOVA categories and in eating duration with the TRE and SDA interventions. During the 
6 month intervention phase, the changes in consumption of NOVA categories (panel (A)) and in eating duration (panels (B,C)) 
showed compliance with time-restricted eating (TRE) and standard dietary advice (SDA) interventions. Numbers above each his-
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in the proportion of unprocessed or minimally processed foods (NOVA1), processed culinary ingredients (NOVA2), processed 
foods (NOVA3), and ultra-processed foods (NOVA4), depicted as % of all classified ingestion events and the number of participants 
per bin is shown on the y-axis. (B) Scatter plot of eating duration during the observation and the intervention phases with TRE (top) 
and SDA (bottom). The dashed line represents an absence of change in eating duration between both study phases. (C) From left to 
right: Changes (x-axis) in eating duration, the start of the eating interval, the midpoint (median) of the eating interval, and the end 
of the eating interval compared to the observation phase, in fractional hours (i.e., 1.33 h = 1 h and 20 min). A shift to the left means 
a shorter eating duration, an earlier start, an earlier midpoint, and an earlier end of the eating interval, respectively. A shift to the 
right means a longer eating duration, a later start, a later midpoint, and a later end of the eating interval, respectively. 
3.5. The Effects of TRE versus SDA on Clinical Outcomes 
We measured the changes in clinical outcomes relative to baseline (Table S3) and 
compared the metabolic effects of TRE and SDA. After 6 months, those randomised to 
TRE lost 1.6% of initial body weight (SD 2.9, p = 0.01), compared to the absence of weight 
loss with SDA (−1.1%, SD 3.5, p = 0.19, Figure 4A). There was no significant difference in 
weight loss between TRE and SDA (between-group difference −0.88%, 95% confidence 
interval −3.1 to 1.3, p = 0.43, similar results with non-parametric tests). Similar results were 
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Figure 3. Changes in the consumption of NOVA categories and in eating duration with the TRE and SDA interventions.
During the 6 month intervention phase, the changes in consumption of NOVA categories (panel (A)) and in eating duration
(panels (B,C)) showed compliance wi h time-restricted eating (TRE) and standard dietary advice (SDA) interventions.
Number abov each hi togram represent the change (unit on the x-axis) as mean (standard deviati n) and p-valu . A)
From left to right: Changes (x-axis) in the proportion of unprocessed or minimally processed foods (NOVA1), processed
culinary ingredients (NOVA2), processed foods (NOVA3), and ultra-processed foods (NOVA4), depicted as % of all classified
ingestion events and the number of participants per bin is shown on the y-axis. (B) Scatter plot of eating duration during
the observation and the intervention phases with TRE (top) and SDA (bottom). The dashed line represents an absence
of change in eating duration between both study phases. (C) From left to right: Changes (x-axis) in eating duration, the
start of the eating interval, the midpoint (median) of the eating interval, and the end of the eating interval compared to the
observation phase, i fractional hours (i.e., 1.33 h = 1 h and 20 min). A shift to the left means a shorter eating duration, an
earlier start, an earlier midpoint, and an earlier end of the eating interval, respectively. A shift to the right means a longer
eating duration, a later start, a later midpoint, and a later end of the eat g interval, respectively.
The timestamp of each ingestion event allowed the assessment of changes in eating
duration during the intervention phase (Figure 3B,C). The TRE intervention shortened the
eating duration compared to baseline (−3.0 h, SD 1.6), which was due to the later start of
the eating interval (+1.5 h, SD 1.1) and an earlier end of the eating interval (−1.4 h, SD
1.1, all p < 0.01). Changes in the eating interval after TRE were all statistically significant
compared to SDA (all p < 0.01 for pairwise comparisons, Table S2).
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The changes in NOVA categories in the SDA arm on the one hand, and changes in
eating duration in the TRE arm on the other hand, confirm that participants followed the
randomly allocated intervention until the closeout visit.
3.5. The Effects of TRE versus SDA on Clinical Outcomes
We measured the changes in clinical outcomes relative to baseline (Table S3) and
compared the metabolic effects of TRE and SDA. After 6 months, those randomised to
TRE lost 1.6% of initial body weight (SD 2.9, p = 0.01), compared to the absence of weight
loss with SDA (−1.1%, SD 3.5, p = 0.19, Figure 4A). There was no significant difference in
weight loss between TRE and SDA (between-group difference −0.88%, 95% confidence
interval −3.1 to 1.3, p = 0.43, similar results with non-parametric tests). Similar results were
obtained in the per-protocol analysis (between-group difference −1.93%, 95% confidence
interval −4.0 to 0.1, p = 0.09).
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haemoglobin, fasting plasma glucose levels (Figure S3), and body composition (Figure 
S4). However, the observed changes in these metabolic outcomes were not statistically 
significant between TRE and SDA (Table 2). In a comparison of BMI categories before and 
after intervention (total n = 45), one participant was overweight at baseline and had a nor-
mal BMI after TRE, while five participants were obese at baseline and overweight after 
intervention (four in SDA, one in TRE arms). Finally, there were no major changes in the 
number of MS diagnoses following the full IDF definition. For those with complete data, 
in the TRE group, five out of 22 participants had MS at baseline, and one more participant 
was diagnosed with MS after intervention. In the SDA group, five out of 18 participants 
had MS at baseline, and one participant “gained” MS diagnosis and one participant “lost” 
MS diagnosis after 6 months. 


































































mean –1.1 (SD 3.5), p = 0.19
SDA










mean –1.6 (SD 2.9), p = 0.01
TRE
A
Figure 4. TRE alters body weight. (A) Change in body weight after time- estrict d eating (TRE, top) compared to standar
dietary advice (SDA, bottom). Data are presented as histograms of w ight change (in % of initial body weight). Numbers
above the histograms represent the weight change as mean (standard deviation) and p-value. (B) Recorded weight
measurements for each participant across multiple visits expressed as a percentage change relative to initial body weight.
V3, randomisation visit; V4, interim visit 2 months post-randomisation; V5, interim visit 4 months post-randomisation;
V6, closeout visit. (C) For each individual (x-axis), the weight change (in % of initial body weight) was estimated using all
recorded weight measurements and a quadratic regression model. The boxes show the 25th, 50th, and 75th percentiles of
estimated weight change, and the whiskers show the 5th and 95th percentiles.
While the average change in weight in both arms was modest, some participants
lost close to 10% of initial body weight (Figure 4B). We next used all recorded weights
to model the weight loss for each individual. We estimate that in the TRE group two
participants significantly gained weight and nine lost weight, whereas in the SDA group
three participants significantly gained weight and six lost weight (Figure 4C). While the
differences between TRE and SDA were not significant, this highlights that the personal
response varied widely between participants, i.e., some lost substantial weight, while
others did not.
We also assessed whether differences were observed in the secondary outcomes, i.e.,
changes in BMI, WC, systolic and diastolic BP, HDL cholesterol, triglycerides, glycated
aemoglobin, fasting plasma glucose levels (Figure S3), and body composition (Figure S4).
However, the observed c anges in these metabolic outcomes were not statistically sig-
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nificant between TRE and SDA (Table 2). In a comparison of BMI categories before and
after intervention (total n = 45), one participant was overweight at baseline and had a
normal BMI after TRE, while five participants were obese at baseline and overweight after
intervention (four in SDA, one in TRE arms). Finally, there were no major changes in the
number of MS diagnoses following the full IDF definition. For those with complete data,
in the TRE group, five out of 22 participants had MS at baseline, and one more participant
was diagnosed with MS after intervention. In the SDA group, five out of 18 participants
had MS at baseline, and one participant “gained” MS diagnosis and one participant “lost”
MS diagnosis after 6 months.
3.6. Weight Loss during the TRE Intervention Is Associated with the Number of Events Recorded
in the Observation Phase
Finally, in the TRE group, we explored potential explanatory variables that were
associated with increased weight loss. While we found no significant association with either
sex, age, weight at baseline, reduction in eating duration or the eating duration during the
intervention phase (Figure 5), we found a positive correlation between the percentage of
weight loss and the number of ingestion events recorded during the observation phase
(p = 0.01, Figure 5G).
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In our study, we characterised the relationship between eating duration, unprocessed 
and processed food consumption, and metabolic health. We found that the number of
unprocessed food events was positively associated with HDL cholesterol and negatively 
associated with BMI and triglycerides. The addition of significant variables from the
NOVA categories, sleep and activity questionnaires improved metabolic health modelling 
compared to just using age and sex. Next, we investigated whether a randomised 6 month 
dietary intervention could lead to weight loss in a pragmatic community-based setting. 
Adults with at least one MS component and eating duration >14 h lost 1.6% (SD 2.9) of 
body weight with a self-selected 12 h TRE, keeping in mind that this intervention group 
was not provided information about standard dietary guidelines. There was no significant 
difference in weight loss between TRE and SDA (between-group difference −0.88%, 95% 
confidence interval −3.1 to 1.3, p = 0.43).
Mobile technologies hold the potential to track daily behaviour and improve meta-
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panel (G): the number of ingestion events recorded during the observation phase (after pre-processing of data as detailed in
Section 2.3). Numbers above the scatter plots represent the Pearson correlation coefficient (Greek letter ρ) and the p-value.
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Table 2. Effects of TRE and SDA on clinical outcomes and eating behaviour.
Time-Restricted Eating (TRE) Standard Dietary Advice (SDA)
Between-
Group Difference
(95% Confidence Interval) b
p for Comparison of
Pre–Post Changes between












Weight, kg 79.6 (15.9) 78.0 (16.4) 0.01 77.5 (13.8) 76.4 (12.7) 0.19 −0.5 (−2.4; 1.4) 0.61
Body mass index, kg/m2 28.0 (4.1) 27.5 (4.3) 0.01 27.0 (4.0) 26.7 (4.0) 0.20 −0.2 (−0.9; 0.4) 0.52
Waist circumference, cm 92.4 (11.6) 90.9 (12.4) 0.04 90.1 (11.0) 88.0 (10.5) 0.09 0.6 (−2.0; 3.2) 0.64
Systolic BP, mmHg 123.8 (11.2) 125.1 (13.4) 0.57 126.4 (10.5) 122.3 (13.5) 0.12 5.5 (−1.2; 12.2) 0.12
Diastolic BP, mmHg 79.3 (11.0) 81.2 (10.7) 0.36 81.0 (9.6) 79.5 (11.0) 0.36 3.5 (−1.7; 8.6) 0.21
HDL cholesterol, mmol/L 1.47 (0.37) 1.46 (0.38) 0.76 1.44 (0.29) 1.41 (0.29) 0.19 0.02 (−0.08; 0.12) 0.70
Triglycerides, mmol/L 1.35 (0.66) 1.24 (0.57) 0.24 1.19 (0.50) 1.03 (0.36) 0.09 0.05 (−0.20; 0.30) 0.69
Fasting plasma glucose, mmol/L 5.21 (0.56) 5.04 (0.53) 0.15 5.17 (0.67) 5.29 (0.55) 0.40 −0.29 (−0.64; 0.07) 0.12
HbA1c, % 5.30 (0.44) 5.33 (0.39) 0.55 5.23 (0.35) 5.14 (0.29) 0.02 0.12 (0.01; 0.23) 0.05
a All p-values for comparisons were calculated with the Student’s t-test. b Mean difference comparing pre–post changes between the TRE and SDA groups (n = 25 and 20, respectively, for weight and body mass
index; n = 24 and 20, respectively, for waist circumference and blood pressure (BP); n = 23 and 18, respectively, for high-density lipoprotein (HDL) cholesterol, triglycerides, fasting plasma glucose and glycated
haemoglobin (HbA1c)).
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4. Discussion
In our study, we characterised the relationship between eating duration, unprocessed
and processed food consumption, and metabolic health. We found that the number of
unprocessed food events was positively associated with HDL cholesterol and negatively
associated with BMI and triglycerides. The addition of significant variables from the
NOVA categories, sleep and activity questionnaires improved metabolic health modelling
compared to just using age and sex. Next, we investigated whether a randomised 6 month
dietary intervention could lead to weight loss in a pragmatic community-based setting.
Adults with at least one MS component and eating duration >14 h lost 1.6% (SD 2.9) of
body weight with a self-selected 12 h TRE, keeping in mind that this intervention group
was not provided information about standard dietary guidelines. There was no significant
difference in weight loss between TRE and SDA (between-group difference −0.88%, 95%
confidence interval −3.1 to 1.3, p = 0.43).
Mobile technologies hold the potential to track daily behaviour and improve metabolic
health. This novel approach offers advantages over more traditional methods, such as food
diaries or food questionnaires, as it avoids memory recall bias and minimises negative
feedback and the Hawthorne observer effect [20]. Close monitoring of eating behaviour can
only be achieved in closed facilities, but this limits the applicability of findings to real-life
settings. Furthermore, smartphone applications can offer more flexibility to participants by
allowing photos to be taken and then annotated at a later time, and the record of consumed
meals can be hidden in order to minimise feedback that may lead to behavioural changes,
which has been successfully used in a previous study [10]. In addition to observing
community-based adults, the data from smartphone apps can help identify participants
that may benefit from dietary interventions and subsequently evaluate compliance.
In our study, the ingestion events were recorded remotely with a smartphone appli-
cation and their level of food processing was assessed with the NOVA classification. We
found a positive correlation between ultra-processed food (NOVA4) consumption and WC.
This is in line with the association of ultra-processed food consumption and obesity in
epidemiological studies in Sweden [40] and the US [41]. In a large longitudinal French
cohort, higher consumption of ultra-processed food was associated with increased BMI
and a higher risk of becoming overweight or developing obesity [42]. At the other end of
the spectrum of food processing, the number of unprocessed food items (NOVA1) showed
the highest number of significant relationships with MS components after age and sex in
our study. The number of unprocessed food events (NOVA1) was positively associated
with HDL and negatively associated with BMI and diastolic BP. Our findings match the rec-
ommendations favouring unprocessed or minimally processed food in everyday diet and
limiting processed food to curtail the obesity epidemic and improve metabolic health [42].
The NOVA classification does not specifically address drinks. Beverages are spread
across NOVA categories following their level of processing: coffee and tea are considered
unprocessed (NOVA1), wine and beer processed through fermentation (NOVA3), while
soda, energy drinks and spirits are ultra-processed (NOVA4). We propose here an extension
to the NOVA classification [22–24] by splitting all ingestion events with beverages into
alcohol-containing drinks (NOVA-A), caffeinated drinks (NOVA-C), sweet drinks (NOVA-
S) and other drinks (NOVA-D). In our study, moderate alcohol consumption was associated
with increased HDL cholesterol [43]. We found a positive association between triglycerides
and caffeinated and sweet drinks. Meta-analysis on the effects of coffee consumption on
serum lipids previously showed a positive dose–response relationship between coffee
intake, cholesterol and triglycerides [44]. Overall, our extension of the NOVA classification
to beverages seems to align with already known metabolic links, and the significant associ-
ations found between the NOVA processed data and clinical measurements demonstrates
the potential of using smartphone food logs for predicting cardiometabolic health.
In a randomised trial, we compared the effects of TRE versus SDA on metabolic health.
We first confirmed compliance with the allocated interventions, thanks to the timestamp
and the text annotation of each ingestion event, respectively. We could also confirm limited
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cross-contamination between both arms, which is a known risk of unblinded trials [39].
Compared to baseline, TRE significantly reduced body weight (−1.6%, SD 2.9), but this
reduction in body weight was not significant when compared to SDA. One possible reason
for the modest reduction in body weight is that the eating window needs to be shorter to
benefit from TRE. Previous studies of TRE reported weight loss with a reduction of eating
duration to 10 h [10,11,15] or even shorter duration (6 h) [18]. In our study, the eating
window was 12 h long for feasibility reasons: The intervention lasted for 6 months and
was trialled in a pragmatic RCT to be applicable to a broader population. Interestingly,
rodent studies have shown a dose–response effect in the prevention of obesity with 8 h
TRE leading to maximum benefits, while 12 h TRE showed fewer benefits [9]. In human
studies, a potential dose–response effect is less clear. This may be explained by the fact that
rodent studies were done during their entire lifespan, while clinical studies are relatively
short compared to the human lifespan. Other explanations of the limited weight loss in
our study might be that the clock time of the eating window might play a role in metabolic
benefits of TRE [18], or that most other studies were conducted in the US where half of the
population have an eating duration > 15 h [10], while the population in our study had a
mean eating duration below 14 h probably for cultural reasons and a lower prevalence of
obesity [1]. Future studies should evaluate more stringent forms of TRE (eating duration
such as 8 or 10 h) with longer follow ups (one year or more) in diverse populations, while
thoroughly checking compliance to the intervention.
Finally, using all weight measurements across five different visits for each individual
showed that some participants seemed to respond well to 12 h TRE, and the estimated
weight loss was significant for nine of the 25 participants. The traditional approach of
calculating % weight change as the difference between baseline and post-intervention
does not provide error estimates for each individual and is sensitive to measurement
error and short-term weight fluctuations. Here, we used multiple weight measurements
over the intervention phase to increase our knowledge of the response of each individual
and provide uncertainty estimates. We found no strong predictors of weight loss and
the heterogeneous response to TRE could arise from personal sensitivity to food timing
or unknown factors. The duration of the TRE window (12 h, instead of a shorter eating
duration, as detailed in the previous paragraph) may explain why weight loss was less
pronounced than the 3.3 kg weight loss used for our sample size calculation. Had the
study been larger, we may have been able to pinpoint underlying predictors explaining
why some participants lost a substantial amount of weight, while others did not. Further
research is needed to reveal the underlying causes.
Our study had several limitations. First, the self-reported ingestion events via a smart-
phone application could be subject to missing ingestion events and missed photographs.
However, the free-text annotation could be added after the meal if it was socially unac-
ceptable or impossible to take a picture at the time. The timestamp of pictures could not
be edited by participants and all smartphones automatically synchronise their date and
time online. The chance of mistimed ingestion events was therefore minimal. Second,
the unblinded nature of the study and the compliance to the intervention are limitations
shared with other trials of dietary interventions [39]. As advised by the CONSORT non-
pharmacological trial guidelines, we assessed compliance with the NOVA classification
and eating duration, but it is technically conceivable that one individual willingly limited
their pictures of food and drinks only within their assigned TRE window, and not outside
of it. We find this unlikely, because a majority of participants reported that it was easy to
use the smartphone application and to take pictures daily.
Our study shows the potential of mobile technologies to record eating behaviour
as part of daily routine and establish relationships with metabolic health. The NOVA
classification proved to be a good compromise for summarising nutrition quality. Specifi-
cally, annotating ingestion events with NOVA categories remained feasible since a fully
quantitative evaluation of eating behaviour is not realistic in large studies. The fact that
the NOVA categories were selected in the regression model justifies the approach, and we
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showed that the inclusion of the smartphone and questionnaire data led to an increase
in predictive performance for metabolic health. The randomised trial of TRE versus SDA
confirmed that a 12 h TRE intervention is feasible over 6 months in a broad population, but
further research is needed to assess how TRE with a shorter eating window may lead to
increased benefits on weight loss and other MS components.
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